The primary focus of the Karakousis Lab is to understand the molecular basis of persistence and reactivation in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). Major research activities include studying the adaptation of M. tuberculosis to stress conditions believed to be important in the infected human host, as well as the phenomenon of phenotypic tolerance to antibiotics. In particular, the regulatory cascade involved in the mycobacterial stringent response is under active investigation. A systems biology-based approach is being used to identify host defense mechanisms responsible for immunological control of M. tuberculosis growth, as well as M. tuberculosis regulatory and metabolic pathways required for bacterial persistence and antibiotic tolerance. The laboratory is also actively investigating the repurposing of various clinically available agents with immune-modulatory properties as adjunctive host-directed therapy, in order to shorten the duration of TB treatment and improve lung pathology. A randomized clinical trial of Statins as Adjunctive Therapy for TB (StAT-TB trial) is investigating the potential adjunctive role of pravastatin in improving microbiological and lung-function outcomes in HIV-infected and uninfected individuals with drug-susceptible, pulmonary TB in South Africa. Recently, the Karakousis Lab has begun developing a novel DNA vaccine targeting conserved regions of SARS-CoV-2, as well as novel immune-modulating therapies for COVID-19.
Statins as Adjunctive, Host-Directed Therapy for TB
The goal of this study is to investigate the potential utility of pravastatin as an adjunctive, host-directed therapy for drug-susceptible pulmonary TB in a two-stage randomized control trial. The primary outcomes of the Stage 1 study are safety and toxicity, and will allow the selection of pravastatin dose for the Stage 2 efficacy study. In the latter, the primary outcomes will include median time to sputum culture conversion and the serial assessment of various subjective and objective measures of lung function. We are also investigating the anti-TB mechanism of action of statins using a variety of high-throughput and targeted molecular approaches.
A novel ‘shock and kill’ strategy for eliminating Mtb persisters in the CD4 T-cell-deficient host
The objective of this study is to determine if pharmacological inhibition of the Mtb stringent response leads to accelerated eradication of TB infection in CD4-deficient mice. The structure activity relationship of various RelMtb inhibitors is being explored.
Immunotherapy Targeting Mtb Persisters in the DC-impaired Setting of HIV and TB
The goal of this research program is to determine whether enhanced immunity to critical components of the Mtb stringent response accelerates immune-based clearance of persistent bacteria and shortens the time required to achieve relapse-free cure in antibiotic-treated mice.
Targeting foam cells as adjunctive TB therapy
The goal of this study is to identify druggable targets in the pro-lipogenic and anti-lipogenic pathways of macrophages, with the long-term goal of shortening the duration of TB treatment and improving TB-related immunopathology.
Evaluation of a novel serum biosignature for detecting TB in HIV-infected individuals
This study will use multiple high-throughput modalities, including LC-MS/MS and RNA-seq, to detect a panel of host metabolites and miRNAs associated with active TB in HIV-infected individuals. Clinical samples are available through the Regional Prospective Observational Research in Tuberculosis (RePORT) International Consortium.
March 25, 2021:
Monika successfully presents her thesis seminar. Congratulations, Dr. Looney!
January 12, 2021:
Carina passed her CMM graduate program oral exams.
December 22, 2020
Petros is elected into the American Society for Clinical Investigation (ASCI):
November 5, 2020
Jennie passed her CMM graduate program oral exams.
September 30, 2020
Harley, Rachel and Jennie publish a review article on antibiotic tolerance in MAC
September 24, 2020
Vignesh publishes a study on hypertension and calcium channel blocker use on TB treatment outcomes
September 22, 2020
Monika publishes her study on tRFs in TB
April 23, 2020
The Karakousis Lab officially embarks on COVID-19 research.
May 14, 2021
The Karakousis lab SGLM and JC will be conducted in conference room 111 at 1-2 pm and via Zoom. Samuel will be presenting SGLM and Vignesh will be presenting the JC.